250
Participants
Start Date
April 9, 2018
Primary Completion Date
April 1, 2032
Study Completion Date
April 1, 2032
ADP adoptive cell therapy
No study drug is administered in this study. Participants who received ADP adoptive cell therapy in a previous trial will be evaluated in this trial for long-term safety and efficacy.
RECRUITING
Peter MacCallum Cancer Centre, Melbourne
RECRUITING
Memorial Sloan Kettering Cancer Center - New York, New York
RECRUITING
University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Pittsburgh
RECRUITING
University of Pennsylvania, Philadelphia
RECRUITING
Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan
COMPLETED
National Cancer Institute - Center for Cancer Research, Bethesda
RECRUITING
ADP Investigational Site, Baltimore
RECRUITING
Duke University Medical Center, Durham
RECRUITING
Emory University School of Medicine, Atlanta
RECRUITING
Hospital Universitario Virgen del Rocío, Seville
RECRUITING
University of Michigan, Ann Arbor
RECRUITING
Uniklinik Köln, Cologne
RECRUITING
Froedtert Hospital, Milwaukee
RECRUITING
Washington University School of Medicine in St. Louis, St Louis
RECRUITING
University of Texas Southwestern Medical Center, Dallas
RECRUITING
University of Texas MD Anderson Cancer Center, Houston
RECRUITING
Klinikum rechts der Isar der Technischen Universität München, Munich
RECRUITING
Oregon Health and Science University, Portland
RECRUITING
Princess Margaret Cancer Centre, Toronto
RECRUITING
Hôpital Maisonneuve-Rosemont, Montreal
RECRUITING
Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam
RECRUITING
University College London Hospitals NHS Foundation Trust, London
RECRUITING
ADP Investigational Site, Manchester
RECRUITING
The Royal Marsden NHS Foundation Trust, Sutton
Lead Sponsor
Adaptimmune
INDUSTRY